Acute Ischemic Stroke Market to Grow Positively at a Paltry CAGR During the Study Period (2019-2032) | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, expected to boost the market

United States, Nevada, Las Vegas, DelveInsight's "Acute Ischemic Stroke - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Acute Ischemic Stroke market share of the individual therapies, current and forecasted Acute Ischemic Stroke market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Ischemic Stroke therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Ischemic Stroke market.
Download sample pages @ https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key highlights of the Acute Ischemic Stroke Market Report:
The total acute ischemic stroke market size was nearly USD 1,300 million in the 7MM in 2022. The Acute ischemic stroke market is expected to grow at a CAGR of 10.67% to hit the USD 4,700 million mark by 2032, aided by the anticipated launch of several promising therapies in the forecast period.
Acute ischemic stroke incidence has been on the rise in young adults. However, the rates of ischemic stroke have declined in older adults.
The American Heart Association/American Stroke Association added a new recommendation section, with the recommendations now grouped based on the etiological subtype.
In 2022, there were over 1.5 million diagnosed incident cases of acute ischemic stroke in the 7MM. It is expected to reach around 2 million cases by 2032, owing to the rising prevalence of stroke risk factors.
The US FDA approved BRILINTA, an oral, reversible, direct-acting P2Y12 receptor antagonist that inhibits platelet, in 2020 to reduce the risk of stroke in patients with an acute ischemic stroke or high-risk TIA.
Genentech Patient Foundation offers a patient assistance program (PAP) for ACTIVASE (alteplase) injection, providing free medicine to patients not covered by insurance.
Glenzocimab, a humanized monoclonal antibody (mAb) fragment that shows antithrombotic action, is being studied as an add-on therapy to thrombolysis. Its administration window is limited to 4.5 h. However, with the potential to overcome complications, glenzocimab can attain a reasonable market share. The mAb is expected to launch in 2025.
The Acute Ischemic Stroke market will experience significant changes during the study period (2019-2032) owing to the expected launch of major late-stage products like glenzocimab, DM199, LT300, nerinetide, BMS-986177/milvexian, and invimestrocel.

Acute Ischemic Stroke Overview

Acute ischemic stroke occurs when a blood clot obstructs a blood vessel in the brain, leading to a sudden reduction or loss of blood flow. This interruption in blood supply results in the deprivation of oxygen and nutrients to brain tissue, causing brain cells to die. It is the most common type of stroke and requires prompt medical intervention to minimize brain damage and improve outcomes.

Causes

The primary cause of acute ischemic stroke is the formation of a blood clot that obstructs a cerebral artery. This can happen due to various underlying conditions:

1. Thrombotic Stroke: A clot forms in one of the brain's arteries, often due to atherosclerosis (buildup of fatty deposits in the arteries).

2. Embolic Stroke: A clot forms elsewhere in the body (often the heart) and travels to the brain, obstructing a cerebral artery. This is commonly associated with:
- Atrial Fibrillation: An irregular heart rhythm that increases the risk of blood clots forming in the heart.
- Heart Valve Disease: Such as rheumatic fever or prosthetic heart valves.
- Recent Heart Attack: Which can contribute to clot formation.

3. Other Risk Factors:
- Hypertension: High blood pressure can damage blood vessels and contribute to clot formation.
- Diabetes: Increases the risk of vascular damage and stroke.
- High Cholesterol: Contributes to atherosclerosis and clot formation.
- Smoking: Increases clotting risk and vascular damage.
- Obesity and Physical Inactivity: Associated with a higher risk of stroke.

Signs and Symptoms

The symptoms of an acute ischemic stroke often come on suddenly and may include:

- Facial Droop: One side of the face may droop or feel numb.
- Arm Weakness: Difficulty lifting or holding up one arm, or sudden weakness in an arm.
- Speech Difficulties: Slurred speech, trouble speaking or understanding speech.
- Sudden Confusion: Difficulty with understanding or forming coherent sentences.
- Vision Problems: Sudden loss or double vision in one or both eyes.
- Dizziness: Loss of balance or coordination, often accompanied by a severe headache.
- Severe Headache: Especially if it is sudden and different from previous headaches.

Diagnosis

Diagnosing an acute ischemic stroke involves:

1. Clinical Evaluation:
- Medical History: Assessing risk factors and symptom onset.
- Physical Examination: Checking for signs of neurological deficits.

2. Imaging Studies:
- CT Scan: Quickly rules out hemorrhagic stroke and identifies ischemic changes.
- MRI: Provides detailed images of brain tissue and can identify early ischemic changes and brain damage.
- CT Angiography (CTA) or MR Angiography (MRA): To visualize blood vessels and identify the location of clots.

3. Blood Tests:
- Complete Blood Count (CBC): To check for infections, anemia, and other conditions.
- Coagulation Profile: To assess blood clotting ability (e.g., INR, PT, PTT).
- Biochemistry: To evaluate electrolytes, glucose levels, and renal function.

4. Additional Tests:
- Carotid Ultrasound: To check for blockages in the carotid arteries.
- Echocardiogram: To evaluate heart function and check for potential sources of emboli.
- Electrocardiogram (ECG): To assess heart rhythm and detect atrial fibrillation.

Treatment Options

Treatment for acute ischemic stroke aims to restore blood flow to the affected part of the brain and minimize damage:

1. Acute Treatments:
- Intravenous Thrombolysis (rtPA): Recombinant tissue plasminogen activator (rtPA) is used to dissolve the blood clot if administered within a 4.5-hour window from symptom onset.
- Endovascular Thrombectomy: Mechanical removal of the clot using a catheter-based procedure, often performed within 6-24 hours of symptom onset, depending on patient criteria.

2. Supportive Care:
- Blood Pressure Management: Monitoring and controlling blood pressure to prevent further damage.
- Blood Sugar Control: Maintaining normal blood glucose levels.
- Fluid and Electrolyte Management: Ensuring proper hydration and electrolyte balance.

3. Secondary Prevention:
- Antiplatelet Agents: Such as aspirin, to prevent future clot formation.
- Anticoagulants: For patients with atrial fibrillation or other conditions increasing clot risk.
- Statins: To manage cholesterol levels and stabilize atherosclerotic plaques.
- Lifestyle Modifications: Encouraging healthy diet, exercise, smoking cessation, and management of underlying conditions (e.g., hypertension, diabetes).

4. Rehabilitation:
- Physical Therapy: To improve movement, strength, and coordination.
- Occupational Therapy: To assist with daily living activities and cognitive rehabilitation.
- Speech Therapy: To address communication difficulties and swallowing problems.

Prognosis

The prognosis for acute ischemic stroke varies depending on the extent of brain damage, the timeliness of treatment, and the patient's overall health. Early intervention can significantly improve outcomes and reduce the risk of long-term disability. However, some patients may experience lasting effects such as motor deficits, speech difficulties, or cognitive impairments. Regular follow-up and rehabilitation are crucial for recovery and minimizing long-term impact.

Acute Ischemic Stroke Epidemiological Insights
According to the World Health Organization (WHO), an estimated 15 million individuals worldwide suffer from stroke each year. Of these, 5 million die, and another 5 million are left permanently disabled.
Request for a sample report @ https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Ischemic Stroke Treatment Market
The therapeutic market for the treatment of Acute Ischemic Stroke (AIS) can be primarily divided into two main categories based on their mechanism of action: thrombolytics and neuroprotective agents. Thrombolytic therapy aims at removing the thrombus blockage and includes drugs that act as recombinant tissue plasminogen activators (rt-PA), antithrombotic agents and platelet aggregation inhibitors. On the other hand, neuroprotective agents act by various mechanisms and are subsequently classified based on their mechanism of action antioxidants, neuron stimulants, calcium channel antagonists and free radical scavengers. Current treatment of AIS is based on the restoration of blood flow to the brain by thrombolysis. Additionally, Activase (Genentech) is approved therapy for the treatment of Acute Ischemic Stroke.
Promising Therapies in the Acute Ischemic Stroke Pipeline
MultiStem
BMS-986177
LT-3001
Elezanumab
And others
Discover more about Acute Ischemic Stroke therapies in the pipeline @ https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Acute Ischemic Stroke Market
Athersys/Healios K.K.
Bristol-Myers Squibb
Lumosa Therapeutics
And others
To understand key companies related to the Acute Ischemic Stroke Market, get a snapshot of the Acute Ischemic Stroke Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Acute Ischemic Stroke Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, and others
Key Acute Ischemic Stroke Pipeline Therapies: MultiStem, BMS-986177, LT-3001, Elezanumab, and others
Therapeutic Assessment: Acute Ischemic Stroke current marketed and emerging therapies
Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute Ischemic Stroke Market Access and Reimbursement
Table of Contents
1. Acute Ischemic Stroke Market Key Insights
2. Acute Ischemic Stroke Market Report Introduction
3. Acute Ischemic Stroke Market Overview at a Glance
4. Acute Ischemic Stroke Market Executive Summary
5. Disease Background and Overview
6. Acute Ischemic Stroke Treatment and Management
7. Acute Ischemic Stroke Epidemiology and Patient Population
8. Patient Journey
9. Acute Ischemic Stroke Emerging Drugs
10. 7MM Acute Ischemic Stroke Market Analysis
11. Acute Ischemic Stroke Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Ischemic Stroke Market Drivers
15. Acute Ischemic Stroke Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.